On March 17, the renowned legal journal International Financial Law Review (IFLR), announced their Asia-pacific awards 2022, where JunHe was awarded the China-equity capital markets firm of the year.

JunHe was one of the first domestic law firms approved to advise on securities and capital markets and has placed this practice area at the core of the firm’s growth and development. JunHe’s capital market team focuses on share issuance, listing and equity financing. This includes share issuances and listings on the Main Board, the SME Board, the GEM Board and the NEEQ, as well as the issuance and listing of H-shares and red chip stocks.

Over the last year, JunHe has completed several milestone projects in the capital market practice area. The firm has gained market recognition in successful projects such as BeiGene’s RMB 20 billion IPO on the SSE STAR Market, BYD’s placement of HKD $30 billion H-shares and the IPO of New Horizon Health, the first early cancer screening company in China, on the Hong Kong Stock Exchange. JunHe completed the Winona’s IPO on the Shenzhen Stock Exchange’s GEM Board, Shanghai Rural Commercial Bank’s IPO on the Main Board of the Shanghai Stock Exchange, and the listing of XPeng Inc. on the Hong Kong Stock Exchange. Other projects include CRCC Heavy Industry’s spin-off from China Railway Construction and its IPO on the SSE Star Market, Xinijang Daqo New Energy’s IPO on the SSE Star Market, and the establishment of SF Real Estate Investment Fund (SF REIT) and its listing on the Main Board of the Hong Kong Stock Exchange.

By the end of 2021, there were 19 Chinese Concept Stocks listed in Hong Kong. JunHe was involved in almost a third of these projects, ranking first in the industry in terms of the number of listings. Chambers and Partners, the world’s leading rating agency for business lawyers, has recognized our excellence in the practice of capital markets, consistently naming JunHe among its “leading law firms.”

JunHe was nominated in the following categories at the IFLR Asia-Pacific Awards:

• China-equity capital markets firm of the year

• China-debt capital markets firm of the year

• China-corporate firm of the year

• Equity deals of the year:

  Establishment of SF REIT and its listing on the Main Board of the Hong Kong Stock Exchange

  Shanghai MicroPort MedBot’s IPO on the Main Board of the Hong Kong Stock Exchange

• Private equity deals of the year:

  CVC Capital / Shiseido personal-care business